Navigation Links
Talecris Biotherapeutics Announces First Quarter 2011 Results
Date:4/27/2011

nation by the European Commission for the development of the company's direct-acting thrombolytic, Plasmin (Human), to treat acute peripheral arterial occlusion (aPAO).  Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot. Through the orphan drug designation, the European Medicines Agency (EMA) will provide Talecris with ten years of marketing exclusivity if the product is the first to be approved in the European Union.  In addition, under this designation, EMA will provide the company with clinical development assistance and reduced regulatory fees.  Talecris received orphan drug designation for Plasmin for aPAO from the U.S. Food and Drug Administration (FDA) in 2009; and
  • During the first quarter, Talecris converted all U.S. sales from Gamunex IGIV labeled product to Gamunex-C IGIV labeled product.  Gamunex-C IGIV is the first and only immune globulin to provide both the intravenous route of administration and a new subcutaneous route of administration.  The intravenous delivery mode is approved to treat primary immune deficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic thrombocytopenic purpura (ITP).  The subcutaneous mode is approved to treat only PI.  A required post-marketing study will be initiated in the second half of 2011.

  • Use of Non-GAAP Financial MeasuresThis press release and the accompanying tables include non-GAAP financial measures including adjusted net income, adjusted diluted EPS, EBITDA, adjusted EBITDA, and Consolidated Cash Flow.  For a description of these non-GAAP financial measures, including the reasons management uses these measures and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with U.S.
    '/>"/>

    SOURCE Talecris Biotherapeutics Holdings Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
    2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
    3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
    4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
    5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
    6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
    7. Talecris Added to NASDAQ Biotechnology Index
    8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
    9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
    10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
    11. Talecris Biotherapeutics Announces Premerger HSR Filing
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... Illinois (PRWEB) October 30, 2014 ... and Cellular Medicine Showcase in Chicago, leading applied ... Orthopedic Surgeon, Dr. Wade McKenna presented talks on ... and Orthopedic Surgical Applications For Stem Cells. , ... amniotic membrane and the properties of AlphaGEMS that ...
    (Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
    (Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
    (Date:10/30/2014)... that devastated a wide swath of Colorado last year ... and other infrastructure had been upgraded or modernized, according ... Denver. , "People need to understand the importance and ... of structural engineering at the CU Denver College of ... "There is an assumption that a bridge will stand ...
    Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2
    ... , PETERSBURG, Va., Nov. 4 Star Scientific, ... the company plans to introduce the CigRx(TM) nutraceutical product developed ... sales in partnership with inVentiv Health, Inc ... of commercialization solutions for every stage of the product lifecycle, ...
    ... EMERYVILLE, Calif., Nov. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ... at the Credit Suisse 18th Annual Healthcare Conference on ... a.m. Pacific Time). Interested parties may access a ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , It is recommended ...
    ... , NORRISTOWN, Pa., Nov. 4 ... company, today announced that it has formed a strategic ... contract research organization that specializes in the agrichemical and ... The exclusive partnership leverages the expertise of industry veteran ...
    Cached Biology Technology:Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 4Emerson Resources Forges Strategic Partnership with Bio Research 2
    (Date:10/29/2014)... by unconventional oil and gas production are well over ... the open access journal Environmental Health . High ... The study is the first to be based on ... and could be used to supplement official air-quality monitoring ... that do not readily flow to the surface. This ...
    (Date:10/29/2014)... 29, 2014, Beaverton, OR) New research presented ... International Conference in Houston, TX showed for the ... HPV infection in women using a readily available ... study, presented by Dr. Judith A. Smith, Pharm.D., ... and Reproductive Sciences at The University of Texas ...
    (Date:10/29/2014)... to make their food, but they also need protection from ... a group of molecules in plants that shields them from ... of the American Chemical Society , one team reports on ... Timothy Zwier and colleagues at Purdue University note that the ... serious damage to plant DNA and, as a result, hinder ...
    Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
    ... COLD SPRING HARBOR, N.Y. (Jan. 5, 2011) Auxin is ... all aspects of plant development and physiology. A new book, ... broad overview of auxin and its many roles in plant biology. ... of plant research," write the editors, Mark Estelle, Dolf Weijers, Karin ...
    ... in children requires special knowledge of growth physiology. Incorrect ... is less often caused by technical deficiencies than by ... group. Using the example of treating fractures of the ... Center, and Lucas Wessel, University Medical Center Mannheim, report ...
    ... research, in association with Elsevier, the leading publisher of ... the 7th NIZO Dairy conference, to be held on ... The conference aims to combine the most recent scientific ... a unique opportunity for experts from academia and the ...
    Cached Biology News:7th NIZO Dairy Conference to focus on flavor and texture, innovations in dairy 2
    Proliferin (C-14)...
    Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
    ... is a dedicated fluorometer with ... kinds of assays in industrial ... clinical applications. Cell biology, immunology ... important application areas. Robot-friendly hardware ...
    ... Thermo Savant's latest SpeedVac Concentrator, the ... and adds a new modern twist., The ... controller and gauge for optimizing runs; preventing ... to be stopped at the end-users preset ...
    Biology Products: